| Treatment period¶ | Post-treatment period+ | |||
| BT group | Sham group | BT group | Sham group | |
| Subjects n | 190 | 96 | 187 | 96 |
| Average duration of period days | 84 | 322 | ||
| Worsening of asthma | 52 | 39 | 27 | 43 |
| Upper respiratory tract infection | 20 | 11 | 30 | 26 |
| Wheezing | 15 | 6 | 4 | 3 |
| Chest pain | 14 | 13 | 3 | 1 |
| Headaches | 14 | 9 | 5 | 3 |
| Dyspnoea | 11 | 6 | 2 | 1 |
| Chest discomfort | 9 | 10 | 2 | 1 |
| Lower respiratory tract infection | 8 | 2 | 3 | 6 |
| Nasopharyngitis | 5 | 7 | 11 | 5 |
| Atelectasis | 5 | 0 | 0 | 0 |
| Bronchitis | 4 | 2 | 7 | 5 |
| Anxiety | 4 | 0 | 1 | 2 |
| Dyspepsia | 4 | 2 | 2 | 4 |
| Haemoptysis | 3 | 0 | 1 | 2 |
| Acute sinusitis | 3 | 2 | 4 | 8 |
| Rhinitis | 2 | 0 | 4 | 6 |
| Influenza | 4 | 2 | 4 | 12 |
| Pyrexia | 4 | 2 | 0 | 1 |
| Hypertension | 3 | 2 | 3 | 3 |
| Urinary tract infection | 1 | 1 | 3 | 1 |
Data are presented as %, unless otherwise stated. #: adverse events >3% frequency that were higher in the BT group compared with the sham treated group; ¶: the period from first treatment to 6 weeks after last treatment; +: the period from 6 weeks post-treatment to 12 months after last treatment. Data from [21].